MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC) is an autoimmune cholangiopathy characterized by chronic inflammation of the biliary epithelium and periductal fibrosis, with no curative treatment available, and liver transplantation is inevitable for end-stage patients. Human placental mesenchymal stem cell (hpMSC)-derived exosomes have demonstrated the ability to prevent fibrosis, inhibit collagen production and possess immunomodulatory properties in autoimmune liver disease. Here, we prepared hpMSC-derived exosomes (ExoMSC) and further investigated the anti-fibrotic effects and detailed mechanism on PSC based on Mdr2−/− mice and multicellular organoids established from PSC patients. The results showed that ExoMSC ameliorated liver fibrosis in Mdr2−/− mice with significant collagen reduction in the preductal area where Th17 differentiation was inhibited as demonstrated by RNAseq analysis, and the percentage of CD4+ IL-17A+ T cells was reduced both in ExoMSC-treated Mdr2−/− mice (Mdr2−/−-Exo) in vivo and ExoMSC-treated Th17 differentiation progressed in vitro. Furthermore, ExoMSC improved the hypersecretory phenotype and intercellular interactions in the hepatic Th17 microenvironment by regulating PERK/CHOP signaling as supported by multicellular organoids. Thus, our data demonstrate the anti-fibrosis effect of ExoMSC in PSC disease by inhibiting Th17 differentiation, and ameliorating the Th17-induced microenvironment, indicating the promising potential therapeutic role of ExoMSC in liver fibrosis of PSC or Th17-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 1×
“…organoids containing multiple cell types, which we herein call composite organoids or multicellular organoids, have been developed and applied in preclinical disease modeling [ 21 ,22 ], tumor microenvironment researching [23] , drug screening [24] , and studies of pathogenic mechanisms [ 25 ,26 ].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Bile acid metabolites control TH17 and Treg cell differentiation
Hang, S., Paik, D., Yao, L., Kim, E., Trinath, J., Lu, J., Ha, S., Nelson, B. N., Kelly, S. P., Wu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1785-z · Cited by 1,457 · cited 1×
“But few treatments were found to regulate cytokines secretion or differentiation of Th17 [ 32 ,33 ].”
BackgroundPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · cited 1×
“…organoids containing multiple cell types, which we herein call composite organoids or multicellular organoids, have been developed and applied in preclinical disease modeling [ 21 ,22 ], tumor microenvironment researching [23] , drug screening [24] , and studies of pathogenic mechanisms [ 25 ,26 ].”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 2×
“…we suspect that the direct role of exosomes in Th17 differentiation is even more pronounced for transcription factors, and primarily mediated through the targeted inhibition of I κ B ζ expression, but the upregulation of Stat3 [34] did not have a persistent effect on the maturation of Th17.”
BackgroundModeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3109 · Cited by 443 · cited 1×
“Then, the downstream effector ATF4 and CHOP were increased upon endoplasmic reticulum stress [71] .”
Background
Cited by
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis
Yao, Q., Wang, B., Yu, J., Pan, Q., Yu, Y., Feng, X., Chen, W., Yang, J., Gao, C., & Cao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.006 · Cited by 24
Self-citationDidamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
“(2), previous reports suggested that the administration of MSC-EXOs has yielded beneficial outcomes in several liver fibrosis models due to their regenerative, immunomodulatory, anti-oxidant, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties [5, 11, 73, 74].”
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
“Chen et al. reported that placental MSC-Exos ameliorated liver fibrosis in Mdr2 −/− mice and multicellular organoids derived from PSC patients, partly by inhibiting Th17 differentiation, improving the hyper-secretory phenotype of cholangiocytes, and regulating HSC-cholangiocyte interaction [202].”
Metadata
- Authors
- Chen, W., Lin, F., Feng, X., Yao, Q., Yu, Y., Gao, F., Zhou, J., Pan, Q., Wu, J., Yang, J., Yu, J., Cao, H., & Li, L.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 19
- Issue
- 1
- Pages
- 100889
- ISSN
- 1818-0876 (ISSN-L)
- OpenAlex
- W4391756050
- Cited by
- 37
- References
- 24
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation. https://app.cochat.ai/papers/10.1016/j.ajps.2024.100889
- The paper
- Chen, W., Lin, F., Feng, X., Yao, Q., Yu, Y., Gao, F., Zhou, J., Pan, Q., Wu, J., Yang, J., Yu, J., Cao, H., & Li, L. (2024). MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation. Asian Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ajps.2024.100889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.